Results 211 to 220 of about 4,307,190 (305)

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

Etiology and Clinical Manifestations of Acute Respiratory Infections in Pediatric Patients: A Retrospective Study in Moscow, Russia. [PDF]

Diseases
Grigoryan DA, Gordukova MA, Galeeva EV, Turina IE, Ligskaya EV, Kovalev OB, Matsvay AD.   +6 more
europepmc   +1 more source

Dose‐related propofol resistance in COVID‐19 patients: Altered drug plasma levels, mechanistic insights from neuronal‐derived extracellular vesicles and miRNA analysis

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Critical care for COVID‐19 patients presents unique challenges, particularly in sedation management. Patients demonstrate notable dose‐related resistance to propofol, potentially due to complex pharmacokinetic alterations. Emerging evidence suggests that plasma extracellular vesicle‐associated miRNA represents valuable predictive ...
Debora Curci, Carlotta Bidoli, Marco Gerdol, Charisse Winston, Robert A. Rissman, Giuliana Decorti, Antonella Fabretto, Andrea Taddio, Gabriele Stocco, Erik Roman‐Pognuz, Marianna Lucafò   +10 more
wiley   +1 more source

Rice-Grain Calcifications: A Classic Sign of Muscular Cysticercosis. [PDF]

Cureus
Soares D, Ferreira I, Sequeira J.
europepmc   +1 more source

Ceftriaxone‐associated immune haemolytic anaemia: A patient‐level systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Ceftriaxone can cause acute haemolysis. Its clinical presentation, risk factors, and outcomes remain incompletely characterized. We conducted a systematic review of published cases with patient‐level data, following international guidelines and with registration in PROSPERO (CRD420261338709). Reports were identified through three bibliographic
Sonja Miotti, Giada Wyttenbach, Mario G. Bianchetti, Camilla Lavagno, Pietro Camozzi, Gregorio P. Milani, Renato Gualtieri, Sebastiano A. G. Lava, Pietro B. Faré, Simone Janett   +9 more
wiley   +1 more source

Influenza A and other respiratory viruses show distinct associations with acute respiratory presentations and temporal correlation with hospital admissions. [PDF]

J Med Microbiol
Husein M, Samara M, Alfarra MR, Al-Kinani A, Al-Dewik N, Coyle PV.   +5 more
europepmc   +1 more source

Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial

British Journal of Clinical Pharmacology, EarlyView.
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich, Franziska Friedrich, Daniel Soriano, Jona Gjeloshi, Björn C. Frye, Xuan Phuoc Nguyen, Lydia Herbstritt, Caroline von Spee‐Mayer, Britta Lang, Fabrice Nollevaux, Andreas Hoheisel, Dorothee Winterberg, Armin Braun, Thomas Epting, Christine Contini, Karl Winkler, Thomas Reinheckel, Franziska C. Trudzinski, Gernot Rohde, Daiana Stolz, Robert Bals, Martin J. Hug, Sebastian Wirtz, Christoph Peters, Carolin Jenkner   +24 more
wiley   +1 more source

The Role of the Medical Laboratory in Identifying 'Super-Spreaders': Correlation Between Viral Load Kinetics and Human-to-Human Infectivity. [PDF]

Rev Med Virol
Gupta Y, Verma A, Bhardwaj Y, Rastogi M, Katiyar A.   +4 more
europepmc   +1 more source

Characterization of Immune Responses to RBD‐SD1 Nanoparticle Vaccines Derived From ACE2‐Capable HKU5‐CoV‐2, NeoCoV, and HKU5 Merbecoviruses

Biotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles presenting HKU5, NeoCoV, and HKU5‐CoV‐2 RBD‐SD1 induced strong, cross‐reactive IgG responses in immunized mice. The surrogate virus neutralization test demonstrated strong activity in sera from homologous vaccination. ABSTRACT Recent discoveries of merbecoviruses such as HKU5, NeoCoV, and HKU5‐CoV‐2 that use angiotensin ...
Peter J. Halfmann, Jeong Soo Lee, Augustine Duffy, Tong Wang, Bingcheng Huang, James Z. Kurdi, Ajay Inampudi, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S. Kane   +11 more
wiley   +1 more source

Impact of SARS-CoV-2 infection and viral burden on outcomes in acute decompensated heart failure. [PDF]

BMC Infect Dis
Nashtar MA, Sehovic H, Salemdawod M, Garipoglu G, Ödemis B, Tzalavras A, Steinmetz M, Canbay A, Özçürümez M, Varnavas V, Patsalis PC, Katsounas A.   +11 more
europepmc   +1 more source